A listed test is not yet a ready testing service.
Emergency listing can shorten one critical part of the access pathway: independent review of product evidence for an emergency context. It does not install instruments, train operators, authorise use in every country, move specimens safely, maintain stock or connect results to public-health action.
WHO announced a new Emergency Use Listing on 2 September for the Xpert Hemorrhagic Fever Panel. The WHO Bundibugyo virus disease diagnostic list, updated on 3 September, records four listed nucleic-acid detection tests: one listed on 2 July, one on 29 July, one on 6 August and the Xpert panel on 1 September. WHO states that products on this list have been assessed only for Ebolavirus/Bundibugyo virus detection claims.
What emergency listing establishes
WHO describes the Emergency Use Listing procedure as a risk-based pathway intended to help UN procurement agencies and Member States assess the acceptability of specific unlicensed products during a public-health emergency, using an essential set of available quality, safety and performance data.
Sourced boundary: WHO states that EUL is not equivalent to WHO prequalification. WHO also states that Member States retain the authority to decide whether an IVD may be used in their country.
Vision interpretation: a listing is an evidence and access milestone, not a universal use permission. Before procurement or deployment, the responsible authority should confirm the exact product, regulatory version, intended-use claim, specimen type, packaging configuration, national pathway and conditions attached to use.
Do not confuse an application with a listing
WHO's separate table of ongoing Bundibugyo virus IVD applications lists additional products at different review stages. WHO explicitly cautions that the table may not reflect the most recent information, does not represent a final EUL decision and should not be used to inform procurement.
Vision interpretation: procurement files should preserve the distinction between products that are listed, products still under assessment and products authorised through a national route. Pipeline visibility can support scenario planning, but only the applicable final decision and its scope should control purchasing and use.
Platform readiness is part of assay readiness
Different test formats create different operating dependencies. A deployable service may depend on a compatible instrument, authorised software, stable power, calibration or verification, maintenance, connectivity, sample-processing materials and trained operators. A product can be listed while a particular site remains unable to run it safely or consistently.
Vision interpretation: map every dependency before allocating tests. Confirm where compatible instruments are located, whether they are operational, which other programmes depend on them, how faults are escalated, what spare capacity exists and how results enter the authorised reporting chain. Installed base is not the same as available capacity.
The specimen pathway remains the first control point
WHO's interim guidance for Ebola and Marburg diagnostic testing addresses the full pathway from specimen collection to analysis and reporting, and emphasizes appropriate biosafety measures for specimens from suspected cases. Laboratory confirmation is important because clinical presentation can overlap with other infections.
Vision interpretation: deployment plans should define who may collect a specimen, which specimen and container are accepted, how identifiers are assigned, how material is packaged and transported, what conditions trigger rejection or referral and where invalid or discordant results are resolved. The analytical step cannot repair a compromised specimen or an unsafe handoff.
Quality oversight must continue after listing
Emergency conditions increase the pressure to move quickly, but speed does not remove the need for lot traceability, control review, competency assessment, nonconformity management or post-deployment monitoring.
Vision interpretation: each testing site should have a documented release pathway and a minimum quality dataset covering controls, invalid and error rates, repeat testing, turnaround time, instrument downtime, reagent lots, storage excursions, corrective actions and operator competency. Trends should be reviewed across the network, not only at individual sites.
Supply planning should follow service demand
Test availability is only one part of continuity. Collection materials, compliant transport packaging, personal protective equipment, disinfectants, controls, instrument consumables, replacement parts, waste handling and trained staff must be available at the same time and place.
Vision interpretation: demand forecasts should be translated into complete testing episodes rather than kit counts. Planners should model suspected-case volume, retesting and invalid rates, geographic allocation, buffer stock, expiry, transport lead time, instrument throughput and downtime. A central stockpile without a replenishment and redistribution rule can still produce local interruption.
Localisation must preserve the listed product identity
Local capability can improve maintenance response, workforce depth, inventory visibility and selected supply-chain resilience. It does not automatically extend a WHO listing to a modified product, a different manufacturing site, a substituted component or a locally adapted workflow.
Vision interpretation: localisation should proceed through documented change control, technology transfer, supplier qualification, validation, regulatory review and lot-release responsibility. The transferred package should cover the quality system, training, service, data and supply model—not equipment alone. Any change that could affect product identity or performance must follow the applicable manufacturer, WHO and national-authority pathways.
The Vision Biotechnology deployment gate
Before a listed assay is treated as operational capacity, decision-makers should be able to answer seven questions:
- Is the exact product and regulatory version listed for the intended claim?
- Has the competent national authority defined or confirmed the route for use?
- Are compatible instruments, software, maintenance and power available at the selected sites?
- Is the specimen-to-result pathway documented, safe and connected to authorised surveillance and response teams?
- Can each site demonstrate operator competency, valid controls, traceability and referral rules?
- Does the supply plan cover the entire testing episode, including buffer stock and downtime?
- Can local support or production expand without an uncontrolled change to the authorised product or workflow?
Vision Biotechnology can support partners with deployment mapping, workflow design, equipment and supply planning, quality-system architecture, training requirements and controlled localisation roadmaps within the applicable national framework. This support does not replace WHO assessment, national authorisation, laboratory verification or public-health authority.
Treat emergency listing as the start of deployment governance. A trustworthy testing service exists only when the listed product, authorised pathway, site capability, specimen controls, quality oversight, reporting route and supply system work together.
Reporting limitations
The cited WHO listing confirms the products and dates recorded for the Bundibugyo virus detection claim. It does not by itself establish country-level authorisation, current stock, price, delivery time, site readiness, installed instrument availability, field utilisation or comparative superiority. Public reports for the listed products were marked as forthcoming on the 3 September list, and WHO notes that application-status tables may lag current review activity.
Primary sources
This article separates WHO-published information from Vision Biotechnology interpretation. It provides general public-health, laboratory, quality-system, procurement-readiness and localisation information; it is not medical advice, a diagnostic recommendation, regulatory approval or a claim about any Vision product. Competent authorities and applicable national procedures remain controlling.